Eric Pauwels
Net Worth
Last updated:
What is Eric Pauwels net worth?
The estimated net worth of Mr. Eric Pauwels is at least $9,771,340 as of 17 Apr 2024. He owns shares worth $3,324,452 as insider, has earned $1,571,188 from insider trading and has received compensation worth at least $4,875,700 in PTC Therapeutics, Inc..
What is the salary of Eric Pauwels?
Mr. Eric Pauwels salary is $975,140 per year as Chief Bus. Officer in PTC Therapeutics, Inc..
How old is Eric Pauwels?
Mr. Eric Pauwels is 63 years old, born in 1962.
What stocks does Eric Pauwels currently own?
As insider, Mr. Eric Pauwels owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
PTC Therapeutics, Inc. (PTCT) | Chief Bus. Officer | 67,694 | $49.11 | $3,324,452 |
What does PTC Therapeutics, Inc. do?
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
Eric Pauwels insider trading
PTC Therapeutics, Inc.
Mr. Eric Pauwels has made 27 insider trades between 2020-2024, according to the Form 4 filled with the SEC. Most recently he sold 787 units of PTCT stock worth $19,781 on 17 Apr 2024.
The largest trade he's ever made was exercising 7,248 units of PTCT stock on 17 May 2023. As of 17 Apr 2024 he still owns at least 67,694 units of PTCT stock.
PTC Therapeutics key executives
PTC Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Allan Steven Jacobson (79) Independent Co-Founder, Chairman of Scientific Advisory Board & Director
- Dr. Neil Almstead (58) Chief Technical Operations Officer
- Dr. Stuart W. Peltz (65) Co-Founder, Chief Executive Officer & Executive Director
- Mr. Eric Pauwels (63) Chief Bus. Officer
- Mr. Mark Elliott Boulding (64) Executive Vice President & Chief Legal Officer
- Ms. Emily Luisa Hill (44) Chief Financial Officer